Predict your next investment

Venture Capital
epidarex.com

See what CB Insights has to offer

Investments

44

Portfolio Exits

5

Funds

3

Partners & Customers

1

About Epidarex Capital

Epidarex Capital, formerly Rock Spring Ventures, funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today's healthcare market. Epidarex invests in early-stage high growth life science and health technology companies in under-ventures markets within the UK and US.

Epidarex Capital Headquarter Location

7910 Woodmont Avenue Suite 1210

Bethesda, Maryland, 20814,

United States

301-298-5455

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Epidarex Capital News

09:00 EDT NodThera Announces Clinical Progress for Lead NLRP3 Inflammasome Inhibitors and Candidate Selection of Novel Brain-Pen...

May 10, 2022

News provided by Share this article Share this article -Lead candidate NT-0796 achieves positive interim results from Phase 1 study, supporting further progression for the treatment of a range of inflammatory diseases- -Second lead candidate NT-0249 advances into first-in-human Phase 1 study to enable clinical development in peripheral chronic inflammatory disease- -Third candidate NT-0527 is announced as a novel brain-penetrant NLRP3 inflammasome inhibitor advancing through IND-enabling studies- LEXINGTON, Mass., May 10, 2022 /PRNewswire/ --  NodThera , a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation, today announced several key advancements across the portfolio. NodThera's lead candidate, NT-0796, demonstrated positive interim results from its Phase 1 single-ascending dose (SAD) study. Additionally, the company has commenced first-in-human dosing in the Phase 1 study of its second lead candidate, NT-0249, and announced the selection of its third pipeline candidate, NT-0527 – a brain-penetrant NLRP3 inflammasome inhibitor from a novel chemotype. The positive interim results from the SAD portion of the Phase 1 trial with NT-0796 represent early clinical proof of mechanism for NT-0796 as a potent NLRP3 inflammasome inhibitor. Across all dosing cohorts, NT-0796 was safe and well tolerated and shown to be orally bioavailable with a dose-proportional pharmacokinetic (PK) profile. This portion of the study also showed a dose-dependent pharmacodynamic (PD) effect through the ability to lower IL-1β and IL-18 levels in an ex vivo NLRP3-stimulation assay. These results confirm the criteria to advance NT-0796 further in development and continue the ongoing multiple-ascending dose (MAD) portion of the Phase 1 study to assess brain exposure through cerebrospinal fluid (CSF) sampling. "NT-0796 has demonstrated robust proof of mechanism and translation from preclinical studies to humans, both validating and further de-risking the development of NT-0796 as a potentially best-in-class, oral, small molecule NLRP3 inflammasome inhibitor," said NodThera's Chief Executive Officer, Adam Keeney. "We are encouraged by these first-in-human results as we work to progress NT-0796 in inflammatory diseases impacting millions of patients, many with limited to no treatment options." Building on successful clinical progress with NT-0796, NodThera has also initiated dosing of the first healthy volunteers in the Phase 1 trial of the company's second lead candidate, NT-0249. NT-0249 is a potent inhibitor of the NLRP3 inflammasome with favorable development characteristics supporting advancement to treat chronic inflammatory diseases of the body. The primary objective of this study will be to assess the safety and tolerability of NT-0249, with secondary objectives to assess the PK and PD (ability to lower IL-1β and IL-18 levels) after single and multiple ascending doses. In addition to advancing two novel candidates into clinical trials, NodThera is further expanding its diverse portfolio with the announcement of NT-0527 as the third oral small molecule NLRP3 inflammasome inhibitor from a novel chemotype to be added to its pipeline. NT-0527 is uniquely designed to inhibit the NLRP3 inflammasome in the brain, with potential to treat a broad range of neuroinflammatory diseases. "Each of NodThera's three portfolio candidates feature unique chemotypes that are distinct from one another, offering specific benefits that can be collectively used to cover a range of inflammatory diseases of the brain and body," shares NodThera's Chief Scientific Officer, Alan Watt. "With the recent addition of NT-0527 as the third candidate in our growing pipeline, NodThera is now advancing novel CNS-penetrant and peripherally-restricted NLRP3 inflammasome inhibitors with differentiated chemistry unlike any other portfolio in the field." About NodThera NodThera is a clinical-stage biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. Led by an experienced management team, NodThera is leveraging new insights into inflammasome biology and chemistry to build a portfolio of highly differentiated small molecule NLRP3 inflammasome inhibitors. The company was founded in 2016 by Epidarex Capital and financed by 5AM Ventures, Cowen Healthcare Investments, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Lexington, MA, with additional locations in Cambridge, UK and Seattle, WA. Learn more at www.nodthera.com or follow us on LinkedIn . SOURCE NodThera

Epidarex Capital Investments

44 Investments

Epidarex Capital has made 44 investments. Their latest investment was in Kynos Therapeutics as part of their Seed VC on April 4, 2022.

CBI Logo

Epidarex Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/7/2022

Seed VC

Kynos Therapeutics

$8.49M

Yes

3

3/2/2022

Series B

Epsilogen

$41.2M

No

10

11/2/2021

Seed VC

Dunad

$24M

Yes

27

10/21/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/29/2021

Series A - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2022

3/2/2022

11/2/2021

10/21/2021

7/29/2021

Round

Seed VC

Series B

Seed VC

Series A

Series A - IV

Company

Kynos Therapeutics

Epsilogen

Dunad

Subscribe to see more

Subscribe to see more

Amount

$8.49M

$41.2M

$24M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

27

10

10

Epidarex Capital Portfolio Exits

5 Portfolio Exits

Epidarex Capital has 5 portfolio exits. Their latest portfolio exit was Sirakoss on November 03, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/3/2020

Acquired

$99M

2

10/7/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/8/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2020

10/7/2020

12/6/2017

11/9/2017

8/8/2017

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Epidarex Capital Fund History

3 Fund Histories

Epidarex Capital has 3 funds, including Epidarex Capital III UK.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/22/2020

Epidarex Capital III UK

$127M

1

5/30/2014

Epidarex Capital UK Life Science & Health Tech Fund

Subscribe to see more

Subscribe to see more

$99M

10

Epidarex Capital III US

Subscribe to see more

Subscribe to see more

10

Closing Date

6/22/2020

5/30/2014

Fund

Epidarex Capital III UK

Epidarex Capital UK Life Science & Health Tech Fund

Epidarex Capital III US

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$127M

$99M

Sources

1

10

10

Epidarex Capital Partners & Customers

1 Partners and customers

Epidarex Capital has 1 strategic partners and customers. Epidarex Capital recently partnered with Selvita on October 10, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

10/31/2016

Partner

Poland

1

Date

10/31/2016

Type

Partner

Business Partner

Country

Poland

News Snippet

Sources

1

Epidarex Capital Team

4 Team Members

Epidarex Capital has 4 team members, including current Managing Partner, A. Sinclair Dunlop.

Name

Work History

Title

Status

A. Sinclair Dunlop

Masa Inc., and New Vantage Group

Managing Partner

Current

Kyparissia Kyp Sirinakis

Managing Partner

Current

Isao Kikuchi

MASA Life Sciences

Managing Director

Former

Samuel Lee

Managing Director

Former

Name

A. Sinclair Dunlop

Kyparissia Kyp Sirinakis

Isao Kikuchi

Samuel Lee

Work History

Masa Inc., and New Vantage Group

MASA Life Sciences

Title

Managing Partner

Managing Partner

Managing Director

Managing Director

Status

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.